Clinical Pathology Integration in Nonclinical Toxicity Studies:
Pulling It All Together
About this webinar
With the ever-increasing number and complexity of available clinical pathology and biomarker assays, the value of dedicated clinical pathology expertise in both safety and clinical studies cannot be overstated. Integration of findings from multiple disciplines into a congruent narrative creates a natural mutual synergy between components of a toxicology report and has become an expectation in contemporary pharmaceutical development.
Instead of simply providing an arbitrary list of statistical differences or values falling out of historical range, clinical pathology data interpreted in the context of findings from other study endpoints (e.g., in-life, pathology, toxicokinetics) creates a natural mutual synergy between disciplines, strengthening the overall scientific value of toxicity studies reports.
This webinar will provide an overview of current clinical pathology reporting practices with emphasis on interpretation and integration of findings with other key study endpoints, including:
- In-life findings
- Veterinary observations
- Anatomic pathology findings
- Traditional and next-generation biomarkers
Who should attend
- Pathologist focused on nonclinical drug development
- Clinical Pathologist supporting nonclinical drug development
- Anatomical Pathology
- Pharmacologic Pathology
- General Toxicologic Pathology
- Clinical Pathology
- Clinical Biomarkers
- Disease Models
- Doctor of Veterinary Medicine (DVM)
- Diplomate, American College of Veterinary Pathologists (DACVP)
- Director/Assoc. Director Clinical Pathology
- Director/Assoc. Director Pathology
- Pathologist
- Senior Pathologist
- Biotech, small, medium, large drug development companies
- North America
What you will learn
- In-life findings
- Veterinary observations
- Anatomic pathology findings
- Clinical pathology findings
- Traditional and next-generation biomarkers
Featured Speakers
Adam Aulbach, DVM, DACVP
Adam Aulbach, DVM, DACVP, is currently the Director of Pathology at Inotiv. He graduated with honors from the University of Missouri College of Veterinary Medicine and completed a residency in toxicologic clinical pathology at Michigan State University in 2007. He served as a Scientific Director in Clinical Pathology at MPI Research, and later, at Charles River Laboratories where he also served as the head of the Biomarker Center of Excellence. His research interests include investigative biomarkers, immunotoxicology and hematotoxicity.
Partner for this event
Inotiv
Inotiv is a pharmaceutical development company providing contract research services to emerging pharmaceutical companies and the world’s leading drug development companies and medical research organizations. Answering the right questions on time and with high-quality data is the key to achieving your drug discovery and development objectives. At Inotiv, diligent clinical decision support is our focus. As a CRO, we deliver the comprehensive and integrated range of right-size toxicology services, analysis, bioanalysis, DMPK and consulting solutions essential to your success.
In choosing a laboratory partner, expect more: more attention, more insight, and a superlative experience. Through scientific leadership and ongoing investments, Inotiv delivers a broad scope of nonclinical and analytical services that will exceed your expectations. Benefit from our long and impeccable regulatory history, world-class team of scientists, and track record of providing attentive, decisive service. Visit us at inotivco.com.
